<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) JULY 17, 1996
ENZON, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
Enzon, Inc. ("Enzon" or the "Company") announced that it has
received three additional United States patents for its Single-Chain
Antigen-Binding (SCA(R)) protein technology, which is one of the Company's
proprietary core technologies.
SCA proteins, like monoclonal antibodies, (MAbs), are used to
deliver therapeutic agents to target disease sites in the body. Enzon
believes SCA proteins offer significant advantages over conventional MAbs
such as greater tumor penetration for cancer imaging and therapy, more
specific localization to targeted disease sites in the body, decreased
immunogenic reactions, and easier, more cost effective manufacturing
processes. In addition to these advantages, because SCA proteins are
developed at the gene level, they are better suited for targeted delivery
of gene therapy vectors and fully-human SCA proteins can be isolated
directly, with no need for costly "humanization" procedures. Also, many
gene therapy methods require that proteins be produced in active form
inside cells. SCA proteins can be produced through intracellular
expression (inside cells) more readily than MAbs.
The SCA patents issued were U.S. Patent No. 5,534,621 covering
immunopurification methods, U.S. Patent No. 5,518,889 covering immunoassay
methods and U.S. Patent No. 5,455,030 covering immunotherapeutic methods.
Enzon has licensed the SCA protein technology primarily on a non-
exclusive basis to more than a dozen companies including several global
pharmaceutical companies such as Baxter Healthcare, Eli Lilly, Bristol-
Myers Squibb, and the Gencell division of Rhone-Poulenc Rorer. Under these
licenses, the Company has received approximately $6 million in up front
payments and is entitled to receive additional payments upon achievement of
specified development milestones and royalties on sales of any future
products developed that utilize Enzon's SCA technology.
Clinical trials for seven products using SCA protein technology
have been started by licensees as well as academic institutions. Some of
the areas being explored are cancer therapy, cardiovascular indications and
AIDS.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: July 22, 1996
ENZON, INC.
(Registrant)
By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer